Quoin Pharmaceuticals clears FDA hurdle for QRX003 peeling skin syndrome trial
Quoin Pharmaceuticals Ltd. has received U.S. Food and Drug Administration clearance for an investigational new drug application covering QRX003 in generalized inflammatory peeling skin syndrome, allowing the Nasdaq-listed rare-disease developer to initiate a Phase 2 trial in the second half of 2026. The study will enroll six to eight pediatric and adult participants in the